Stay updated with the Cipla Stock Liveblog, your one-stop destination for real-time information and analysis of a leading ...

Cipla faces headwinds but remains resilient with strong product portfolio, robust earnings growth potential, and reasonable ...

Stay up-to-date with the Cipla Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent ...

Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...

Jio Financial Services, IOB, NBCC, Indian Oil, IRFC, Exide Industries, Cipla and ACC shares top stocks to buy recommendation ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

Under this agreement, Cipla has exclusive rights to market the innovative treatment for post-operative inflammation and pain ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Cipla has announced an exclusive licensing agreement ... across 11 countries, including India. It is used to treat post-op inflammation and pain following ocular surgery.